B.Riley analyst Mayank Mamtani reiterated a Buy rating and $670.00 price target on Madrigal Pharmaceuticals (NASDAQ: MDGL).The analyst comments "Rezdiffra ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE